Dear editor,

We would like to update the readership of **einstein** (São Paulo) on the information given in page 6, regarding hyaluronidase facilitated subcutaneous immunoglobulin, in the article entitled II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies published in this journal in volume 15 issue 1, 2017.^(^ [@B1] ^)^

When the article was written information available was that hyaluronidase facilitated subcutaneous immunoglobulin was not approved to be used by children and pregnant women, even in countries that the product is commercially available. However, in Europe the product is approved to be used by children of any age since July 2016.^(^ [@B2] ^--^ [@B4] ^)^ The hyaluronidase facilitated subcutaneous immunoglobulin infusion use in pregnant women, however, is still under investigation^(^ [@B4] ^)^

To correct this information is relevant because it guarantees that our article can provide the most accurate information as possible. In addition, patients should learn about the availability of this new therapeutic resource until this medication becomes approved in our country.
